Fusen Pharmaceutical Company Limited (HKG:1652)
Hong Kong
· Delayed Price · Currency is HKD 1.130
-0.030 (-2.59%)
Apr 29, 2026, 3:57 PM HKT
HKG:1652 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Revenue | 273.37 | 326.03 | 565.61 | 491.76 | 385.66 | Upgrade
|
| Revenue Growth (YoY) | -16.15% | -42.36% | 15.02% | 27.51% | -20.78% | Upgrade
|
| Cost of Revenue | 163.58 | 163.39 | 266.1 | 266.74 | 174.53 | Upgrade
|
| Gross Profit | 109.79 | 162.64 | 299.51 | 225.02 | 211.13 | Upgrade
|
| Selling, General & Admin | 97.12 | 141.28 | 214.44 | 173.47 | 156.18 | Upgrade
|
| Research & Development | 13.29 | 106.26 | 65.2 | 15.18 | - | Upgrade
|
| Other Operating Expenses | -17.44 | -17.73 | -1.58 | -9.03 | -10.97 | Upgrade
|
| Operating Expenses | 118.91 | 229.81 | 278.05 | 179.61 | 145.22 | Upgrade
|
| Operating Income | -9.12 | -67.18 | 21.45 | 45.41 | 65.92 | Upgrade
|
| Interest Expense | -20.36 | -20.14 | -12.58 | -12.38 | -8.24 | Upgrade
|
| Interest & Investment Income | 0.02 | 0.02 | 0.42 | 1.97 | 2.56 | Upgrade
|
| Earnings From Equity Investments | 14.45 | -104.1 | -40.62 | -21.02 | -1.97 | Upgrade
|
| Currency Exchange Gain (Loss) | - | 1.28 | 3.32 | -5.32 | -1.41 | Upgrade
|
| EBT Excluding Unusual Items | -15 | -190.11 | -28.01 | 8.67 | 56.85 | Upgrade
|
| Gain (Loss) on Sale of Investments | 0.59 | -0.34 | -0.31 | -37.99 | -21.02 | Upgrade
|
| Gain (Loss) on Sale of Assets | 6.81 | 0 | -1.12 | -1.67 | -12.04 | Upgrade
|
| Pretax Income | -7.6 | -190.45 | -29.45 | -30.99 | 23.79 | Upgrade
|
| Income Tax Expense | 4.2 | -1.65 | 6.85 | 3.66 | 7.18 | Upgrade
|
| Earnings From Continuing Operations | -11.8 | -188.8 | -36.3 | -34.65 | 16.61 | Upgrade
|
| Minority Interest in Earnings | 0.02 | 0.02 | 0.02 | 0.05 | 0.03 | Upgrade
|
| Net Income | -11.78 | -188.78 | -36.28 | -34.61 | 16.65 | Upgrade
|
| Net Income to Common | -11.78 | -188.78 | -36.28 | -34.61 | 16.65 | Upgrade
|
| Net Income Growth | - | - | - | - | -76.27% | Upgrade
|
| Shares Outstanding (Basic) | 739 | 740 | 752 | 756 | 770 | Upgrade
|
| Shares Outstanding (Diluted) | 739 | 740 | 752 | 756 | 770 | Upgrade
|
| Shares Change (YoY) | -0.09% | -1.60% | -0.53% | -1.85% | -2.51% | Upgrade
|
| EPS (Basic) | -0.02 | -0.26 | -0.05 | -0.05 | 0.02 | Upgrade
|
| EPS (Diluted) | -0.02 | -0.26 | -0.05 | -0.05 | 0.02 | Upgrade
|
| EPS Growth | - | - | - | - | -77.58% | Upgrade
|
| Free Cash Flow | - | 72.77 | -86.42 | 86.63 | -62.37 | Upgrade
|
| Free Cash Flow Per Share | - | 0.10 | -0.12 | 0.12 | -0.08 | Upgrade
|
| Dividend Per Share | - | - | - | - | 0.009 | Upgrade
|
| Gross Margin | 40.16% | 49.88% | 52.95% | 45.76% | 54.74% | Upgrade
|
| Operating Margin | -3.34% | -20.60% | 3.79% | 9.23% | 17.09% | Upgrade
|
| Profit Margin | -4.31% | -57.90% | -6.41% | -7.04% | 4.32% | Upgrade
|
| Free Cash Flow Margin | - | 22.32% | -15.28% | 17.62% | -16.17% | Upgrade
|
| EBITDA | 25.55 | -32.5 | 49.56 | 72.33 | 83.35 | Upgrade
|
| EBITDA Margin | 9.35% | -9.97% | 8.76% | 14.71% | 21.61% | Upgrade
|
| D&A For EBITDA | 34.68 | 34.68 | 28.1 | 26.92 | 17.43 | Upgrade
|
| EBIT | -9.12 | -67.18 | 21.45 | 45.41 | 65.92 | Upgrade
|
| EBIT Margin | -3.34% | -20.60% | 3.79% | 9.23% | 17.09% | Upgrade
|
| Effective Tax Rate | - | - | - | - | 30.17% | Upgrade
|
| Advertising Expenses | 32.55 | - | - | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.